Shots:

• The approval is based on P-II STARTRK-2 study assessing the efficacy of Rozyltrek in ROS1 fusion-positive NSCLC cohort while the safety is evaluated in two P-I studies (STARTRK-1 study and ALKA-372-001 study)
• Additionally- Chugai receives MHLW’s approval for Alecensa (alectinib hydrochloride) and Rituxan to treat r/r ALK-positive ALCL) and ATTP respectively
• Rozlytrek is an oral tyrosine kinase inhibitor targeting ROS1 & TRK while Rituxan is an anti-CD20 mAb- co-marketed by Zenyaku and Chugai in Japan

Source 1- Source 2- Source 3 ­to­ read full press release/ article | Ref: Chugai  | Image: Chugai